Dearborn Partners LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 289,247 shares of the company’s stock after buying an additional 3,896 shares during the period. Johnson & Johnson accounts for about 3.0% of Dearborn Partners LLC’s portfolio, making the stock its largest position. Dearborn Partners LLC’s holdings in Johnson & Johnson were worth $35,085,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the stock. CHURCHILL MANAGEMENT Corp boosted its stake in shares of Johnson & Johnson by 51.4% in the first quarter. CHURCHILL MANAGEMENT Corp now owns 135,013 shares of the company’s stock valued at $14,608,000 after buying an additional 45,845 shares during the last quarter. Independent Portfolio Consultants Inc. boosted its stake in Johnson & Johnson by 340.1% in the first quarter. Independent Portfolio Consultants Inc. now owns 3,076 shares of the company’s stock worth $333,000 after buying an additional 2,377 shares in the last quarter. Swarthmore Group Inc. boosted its stake in Johnson & Johnson by 36.7% in the first quarter. Swarthmore Group Inc. now owns 22,725 shares of the company’s stock worth $2,459,000 after buying an additional 6,100 shares in the last quarter. Sit Investment Associates Inc. boosted its stake in Johnson & Johnson by 10.3% in the first quarter. Sit Investment Associates Inc. now owns 792,920 shares of the company’s stock worth $85,794,000 after buying an additional 73,790 shares in the last quarter. Finally, Eastern Bank boosted its stake in Johnson & Johnson by 1.2% in the first quarter. Eastern Bank now owns 191,990 shares of the company’s stock worth $20,774,000 after buying an additional 2,230 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) traded up 0.41% during midday trading on Friday, hitting $119.24. 4,799,292 shares of the stock were exchanged. The firm’s 50-day moving average is $118.85 and its 200 day moving average is $117.07. Johnson & Johnson has a 52 week low of $94.12 and a 52 week high of $126.07. The stock has a market cap of $326.23 billion, a price-to-earnings ratio of 22.22 and a beta of 0.62.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The business had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Equities research analysts expect that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

A number of analysts have weighed in on JNJ shares. Goldman Sachs Group Inc. set a $121.00 price target on Johnson & Johnson and gave the company a “neutral” rating in a research note on Monday, June 13th. Jefferies Group restated a “hold” rating and issued a $109.00 price target (up from $108.00) on shares of Johnson & Johnson in a research note on Tuesday, June 14th. Barclays PLC restated an “overweight” rating and issued a $125.00 price target (up from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Wells Fargo & Co. restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. Finally, Royal Bank Of Canada raised their price target on Johnson & Johnson from $125.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, July 20th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $120.19.

In related news, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.